Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study
Authors:
- 13 November 2009
- journal article
- other
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 15 (12) , 1481-1488
Abstract
Neutralizing antibodies against interferon-beta are associated with a reduction of the efficacy of this drug. Continuing treatment leads to a decline or even loss of neutralizing antibodies over years. No strategies are currently available to shorten the period of neutralizing antibody positivity. The objective of this study was to investigate the effect of switching between high and low immunogenic interferon-beta products on neutralising antibody titres. Twenty-four patients treated with the subcutaneously administered interferon-beta 1b or 1a and high titres of neutralizing antibodies were included. At baseline interferon-beta therapy was interrupted for 3 months and two pulses of high dose methylprednisolone were applied. Patients were then randomized to receive either the previous interferon-beta preparation or the low immunogenic intramuscular interferon-beta 1a. The primary end-point was the change of neutralizing antibody titres 12 months after randomization. Twelve patients were switched to interferon-beta 1a intramuscularly and 12 patients remained on previous treatment. Median neutralizing antibody titres were 846 NU at baseline and 196 NU at the end of the study. The median change of neutralizing antibody titres did not differ significantly between therapy switchers and non-switchers. Baseline and final neutralizing antibody titres correlated significantly. In conclusion, neither switching nor continuous therapy with any subcutaneous interferon-beta preparation significantly changed neutralizing antibody titres.Keywords
This publication has 22 references indexed in Scilit:
- Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon‐βEuropean Journal of Neurology, 2008
- The implications of immunogenicity for protein-based multiple sclerosis therapiesJournal of the Neurological Sciences, 2008
- The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosisCurrent Medical Research and Opinion, 2005
- Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosisEuropean Journal of Neurology, 2005
- Appearance and disappearance of neutralizing antibodies during interferon-beta therapyNeurology, 2005
- PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MSNeurology, 2001
- Stroke following internal carotid artery occlusion — a contra‐indication for intravenous thrombolysis?European Journal of Neurology, 1999
- A Novel Bioassay for the Determination of Neutralizing Antibodies to IFNβ1bJournal of Interferon & Cytokine Research, 1998
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- An Analysis of Neutralization Reaction of Interferon by Antibody: A Proposal on the Expression of Neutralization TiterJournal of Interferon Research, 1980